PT - JOURNAL ARTICLE AU - Dickson W.L. Wong AU - Barbara M. Klinkhammer AU - Sonja Djudjaj AU - Sophia Villwock AU - M. Cherelle Timm AU - Eva M. Buhl AU - Sophie Wucherpfennig AU - Claudio Cacchi AU - Till Braunschweig AU - Ruth Knüchel-Clarke AU - Danny Jonigk AU - Christopher Werlein AU - Roman D. Bülow AU - Edgar Dahl AU - Saskia von Stillfried AU - Peter Boor TI - Multisystemic cellular tropism of SARS-CoV-2 in autopsies of COVID-19 patients AID - 10.1101/2021.06.03.21258241 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.03.21258241 4099 - http://medrxiv.org/content/early/2021/06/05/2021.06.03.21258241.short 4100 - http://medrxiv.org/content/early/2021/06/05/2021.06.03.21258241.full AB - Background Multiorgan tropism of SARS-CoV-2 has previously been shown for several major organs.Methods We have comprehensively analyzed 25 different formalin-fixed paraffin-embedded (FFPE) tissues/organs from autopsies of fatal COVID-19 cases (n=8), using detailed histopathological assessment, detection of SARS-CoV-2 RNA using polymerase chain reaction and RNA in situ hybridization, viral protein using immunohistochemistry, and virus particles using transmission electron microscopy. Finally, we confirmed these findings in an independent external autopsy cohort (n=9).Findings SARS-CoV-2 RNA was mainly localized in epithelial cells, endothelial and mesenchymal cells across all organs. Next to lung, trachea, kidney, heart, or liver, viral RNA was also found in tonsils, salivary glands, oropharynx, thyroid, adrenal gland, testicles, prostate, ovaries, small bowel, lymph nodes, skin and skeletal muscle. Viral RNA was predominantly found in cells expressing ACE2, TMPRSS2, or both. The SARS-CoV-2 replicating RNA was also detected in these organs. Immunohistochemistry and electron microscopy were not suitable for reliable and specific SARS-CoV-2 detection in autopsies. The findings were validated using in situ hybridization on external COVID-19 autopsy samples. Finally, apart from the lung, correlation of virus detection and histopathological assessment did not reveal any specific alterations that could be attributed to SARS-CoV-2.Interpretation SARS-CoV-2 could be observed in virtually all organs, colocalizing with ACE2 and TMPRSS2 mainly in epithelial but also in mesenchymal and endothelial cells, and viral replication was found across all organ systems. Apart from the respiratory tract, no specific (histo-)morphologic alterations could be assigned to the SARS-CoV-2 infection.Evidence before this study SARS-CoV-2 has been shown to infect the respiratory tract and affect several other major organs. However, on a cellular level, the localization of SARS-CoV-2 and its targets ACE2 and TMPRSS2 have not been described comprehensively.Added value of this study We have analyzed tissue SARS-CoV-2 RNA using RT-PCR and visualized its localization together with ACE2 and TMPRSS2 using in situ hybridization (ISH) in 25 different autopsy tissues. SARS-CoV-2 sense and antisense RNA were detected in 16 tissues/organs, mainly in epithelial cells and, to a lesser extent, in endothelial or stromal cells. Detection of viral protein using immunohistochemistry or viral particles using transmission electron microscopy did not yield specific results. Interestingly, apart from the respiratory tract and specifically the lungs, we have not found a specific pathology that would be associated with extrapulmonary viral spread.Implications of all the available evidence We provide a recommendation on using these methods in autopsy diagnostics for SARS-CoV-2. Our data extend the current hypothesis of severe COVID-19 being multisystemic diseases. Our data also provide clear evidence of infection and replication of SARS-CoV-2 in the endothelial cell across all organs, extending the hypothesis on the (micro)vascular involvement in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the German Registry of COVID-19 Autopsies (www.DeRegCOVID.ukaachen.de), funded Federal Ministry of Health (ZMVI1-2520COR201), by the Federal Ministry of Education and Research within the framework of the network of university medicine (DEFEAT PANDEMICs, 01KX2021 and STOP-FSGS-01GM1901A), the German Research Foundation (DFG; SFB/TRR219 Project-ID 322900939, BO3755/13-1 Project-ID 454024652, and DJ100/1-1 432698239), the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 101001791), RWTH START-program (125/17 and 109/20) and the grant of the European Research Council (ERC); European Consolidator Grant, XHale to Danny Jonigk (ref. no.771883).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was given ethical approval by the ethics committee at the medical faculty of RWTH Aachen University (EK 304/20, EK 119/20, EK 092/20 and 9621_BO_K_2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and analyzed within the current study are not publicly available due to protecting the study participant privacy but are available from the corresponding author on reasonable request.